Return to top of page

Alliance Weighs in on Importance of Treatment Options for Sinus Congestion

Published September 8, 2023

Medications and personal care items organized on drug store shelves.

Today, the Alliance and the American Society of Consultant Pharmacists (ASCP) submitted comment to the U.S. Food & Drug Administration (FDA) on the importance of access to treatment options for over-the-counter decongestants. The FDA is currently evaluating the efficacy of such treatments.

In the letter, the Alliance and ASCP discuss consumers’ self-reported benefits for individuals using phenylephrine (PE) medications, and the lack of over-the-counter alternatives to PE. The main therapeutic alternative to PE, pseudophedrine (PSE), is subject to additional restrictions and is only available over-the-counter. If PE is taken off the market, this leaves PSE as the only option and this is available in fewer settings and only when a pharmacy is open. Based on these factors, the Alliance and ASCP recommended the FDA continue to recognize PE as a decongestant.

Read the full letter.

News & Updates